AI in Biotechnology Market - Global Forecast to 2029
商品番号 : SMB-68260
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年2月 |
| ページ数 | 397 |
| 図表数 | 525 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The global AI in biotechnology market is projected to reach USD 7.75 billion by 2029 from USD 3.23 billion in 2024, at a high CAGR of 19.1% during the forecast period.
バイオテクノロジーにおける世界のAI市場は、予測期間中に19.1%という高いCAGRで、2024年の32億3,000万米ドルから2029年までに77億5,000万米ドルに達すると予測されています。
The market is expected to grow as a result of the increasing demand for personalized therapies and precision medicines, and the growing applications of AI in epidemiological models for predicting disease outbreaks. It helps public health officials to respond and develop better vaccines which further drives market growth. The increasing demand for personalized therapies and precision medicine has led to an increasing number of clinical trials performed. For instance, as of October 2023, around 1584 clinical trials performed using AI for various diseases were reported to Clincaltrials.gov. However, the limited interpretability of AI algorithms, high implementation cost and data privacy & security concerns are some of the restraining factors for the market growth.
この市場は、個別化された治療法や精密医療に対する需要の高まり、病気の発生を予測するための疫学モデルにおける AI の応用の拡大により、成長すると予想されています。これは、公衆衛生当局が対応し、より優れたワクチンを開発するのに役立ち、市場の成長をさらに促進します。個別化された治療法と精密医療に対する需要の高まりにより、実施される臨床試験の数が増加しています。たとえば、2023 年 10 月の時点で、さまざまな疾患に対して AI を使用して実施された約 1584 件の臨床試験が Clincaltrials.gov に報告されています。ただし、AI アルゴリズムの解釈可能性の制限、実装コストの高さ、データのプライバシーとセキュリティの懸念は、市場の成長を抑制する要因の一部となっています。
“Based on function, research & development segment dominated the AI in biotechnology market in 2023”
The AI in biotechnology market by function is broadly divided into six segments: research & development, regulatory compliance, manufacturing & supply chain, launch & commercial, and post-market surveillance & patient support. The research & development segment accounted for the largest share of the global AI in biotechnology market in 2023. The large share of this segment can be attributed to the rising demand for personalized medicine, automation in labs, the rise of predictive analytics, and the need for faster drug discovery. an increase in the number of AI-discovered molecules in clinical trials significantly augments market growth. For instance, AI-native Biotechs and their partners in the pharmaceutical industry have entered an increasing number of molecules for AI-driven clinical trials (Source: Elsevier B.V.). In 2023, there were around 67 reported ongoing trials, and this number has increased from 2014 with around 60% year-over-year compound growth.
“In 2023, the pharmaceutical companies held the largest market share among end users.”
Based on end user, pharmaceutical companies hold the largest share of the AI in biotechnology market. There are emerging health problems, notably cognitive decline that led to high healthcare services and medication demands, associated with such demographic shifts. Pharmaceutical companies will experience huge growth opportunities as life expectancy increases, thereby raising the increasing healthcare demands of this aging population. Additionally, massive investments are being made by pharmaceutical companies into research and development, particularly drug discovery and development processes wherein AI is utilized for tasks like target identification, lead optimization, and patient stratification in clinical trials.
“In 2023, Europe was the second largest regional market for AI in the biotechnology market.”
In 2023, Europe held the second-highest share of the AI in biotechnology market. This dominance is attributed to a substantial increase in investment in Europe for AI, with a growing number of patent filings for biotechnology-related medical technology. In the year 2022, the European Patent Office (EPO) published over 10,000 AI patent applications, which highlights an increased focus on AI solutions in biotechnology. In March 2023, the UK government pledged investment in nine promising AI healthcare technologies to speed up research and development. Moreover, in August 2023, the government launched 22 new projects to explore the application of AI in healthcare. All these initiatives represent Europe’s determination to spearhead applications of AI in the biotechnology sector.
The break-down of primary participants is as mentioned below:
- By Company Type – Tier 1: 45%, Tier 2: 30%, and Tier 3: 25%
- By Designation – C-level: 42%, Director-level: 31%, and Others: 27%
- By Region – North America: 32%, Europe: 32%, Asia Pacific: 26%, Middle East & Africa: 5%, Latin America: 5%
NVIDIA Corporation (US), Illumina, Inc. (US), Exscientia plc (UK), Schrödinger, Inc. (US), Recursion Pharmaceuticals, Inc. (US), SOPHiA GENETICS (Switzerland), Predictive Oncology. (US), Deep Genomics. (Canada), ), Data4Cure, Inc. (US), Genoox (US), BenevolentAI (US), and DNAnexus, Inc. (US) are some of the key players in the AI in biotechnology market.
The study includes an in-depth competitive analysis of these key players in AI in biotechnology market, with their company profiles, recent developments, and key market strategies.
Research Coverage:
The report analyses the AI in biotechnology market. It aims to estimate the market size and future growth potential of various market segments based on offering (end-to-end solutions, niche solutions, technology providers, and services), function (research & development [R&D], regulatory compliance, manufacturing & supply chain, launch & commercial, post-market surveillance & patient support, and corporate), deployment mode (cloud-based, and on-premise), end-user (pharmaceutical companies, biotechnology companies, research institutes and labs, healthcare providers, and contract research organizations [CRO]), and region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa).
The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the AI in biotechnology market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; partnerships, collaborations, acquisitions, expansion, agreements, investment, and product launches associated with the AI in biotechnology market. Competitive analysis of upcoming startups in the AI in biotechnology market ecosystem is covered in this report.
Reasons to Buy the Report
This report will enrich established firms and new entrants/smaller firms to gauge the market’s pulse, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.
This report provides insights on:
Analysis of key drivers: (growing cross-industry collaborations and partnerships, growing need to reduce the time and cost of drug discovery and development, rising adoption of AI in precision medicine, improving computing power, and declining hardware cost), restraints (high implementation costs of AI limit adoption in biotechnology, especially for SMEs and emerging economies, data privacy risks and compliance challenges for AI in biotechnology), opportunities (integrating AI and big data in precision medicine for biotechnology advancement, surge in biotechnology investments enhances opportunities for AI to accelerate drug discovery innovations, innovation across healthcare, agriculture, and environmental science for global growth), and challenges (data quality and interpretability issues that hinder AI integration and trustworthiness, AI deployment in biotechnology hindered by talent shortages and evolving regulatory challenges) influencing the growth of the AI in biotechnology market.
Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the AI in biotechnology market.
Market Development: Comprehensive information on the lucrative emerging markets, by offering, function, deployment mode, end-user, and region.
Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the AI in biotechnology market.
Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the AI in biotechnology market including NVIDIA Corporation (US), Illumina, Inc. (US), Exscientia (UK), Schrödinger, Inc. (US), Recursion Pharmaceuticals, Inc. (US), SOPHiA GENETICS (Switzerland), Predictive Oncology. (US),Deep Genomics. (Canada), Exscientia (US), and Data4Cure, Inc.
Table of Contents
1 INTRODUCTION 37
1.1 STUDY OBJECTIVES 37
1.2 MARKET DEFINITION 37
1.3 STUDY SCOPE 38
1.3.1 MARKETS COVERED & REGIONAL SCOPE 38
1.3.2 INCLUSIONS & EXCLUSIONS 39
1.3.3 YEARS CONSIDERED 40
1.4 CURRENCY CONSIDERED 41
1.5 LIMITATIONS 41
1.6 STAKEHOLDERS 42
2 RESEARCH METHODOLOGY 43
2.1 RESEARCH DATA 43
2.1.1 SECONDARY DATA 44
2.1.1.1 Key data from secondary sources 45
2.1.2 PRIMARY DATA 45
2.1.2.1 Key data from primary sources 47
2.1.2.2 Insights from primary experts 48
2.2 MARKET SIZE ESTIMATION 49
2.3 DATA TRIANGULATION 53
2.4 MARKET SHARE ESTIMATION 54
2.5 RESEARCH ASSUMPTIONS 54
2.6 LIMITATIONS 54
2.6.1 METHODOLOGY-RELATED LIMITATIONS 54
2.6.2 SCOPE-RELATED LIMITATIONS 54
2.7 RISK ASSESSMENT 55
3 EXECUTIVE SUMMARY 56
4 PREMIUM INSIGHTS 60
4.1 AI IN BIOTECHNOLOGY MARKET OVERVIEW 60
4.2 AI IN BIOTECHNOLOGY MARKET, BY REGION 61
4.3 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER & REGION 62
4.4 AI IN BIOTECHNOLOGY MARKET: GEOGRAPHIC SNAPSHOT 63
4.5 AI IN BIOTECHNOLOGY MARKET: DEVELOPED VS. EMERGING ECONOMIES 63
5 MARKET OVERVIEW 64
5.1 INTRODUCTION 64
5.2 MARKET DYNAMICS 64
5.2.1 DRIVERS 65
5.2.1.1 Growing cross-industry collaborations and partnerships 65
5.2.1.2 Growing need to reduce time and cost of drug discovery and development 66
5.2.1.3 Rising adoption of AI in precision medicine 66
5.2.1.4 Improving computing power and declining hardware cost 67
5.2.2 RESTRAINTS 68
5.2.2.1 High implementation costs of AI limit adoption in biotechnology, especially for SMEs and emerging economies 68
5.2.2.2 Data privacy risks and compliance challenges for AI in biotechnology 68
5.2.3 OPPORTUNITIES 69
5.2.3.1 Integrating AI and big data in precision medicine for biotechnology advancement 69
5.2.3.2 Surge in biotechnology investments enhances opportunities for AI to accelerate drug discovery innovations 70
5.2.3.3 Innovation across healthcare, agriculture, and environmental science for global growth 70
5.2.4 CHALLENGES 70
5.2.4.1 Data quality and interpretability issues that hinder AI integration and trustworthiness 70
5.2.4.2 AI deployment in biotechnology hindered by talent shortages and evolving regulatory challenges 71
5.3 ECOSYSTEM ANALYSIS 72
5.4 CASE STUDY ANALYSIS 73
5.4.1 LEVERAGED NVIDIA DGX CLOUD FOR RAPID TRAINING OF PROTEIN MODELS 73
5.4.2 IMPLEMENTED END-TO-END NGS WORKFLOW FOR EFFICIENT GENETIC VARIANT DETECTION 73
5.4.3 ACCELERATED DRUG DISCOVERY WITH GENERATIVE AI AND STREAMLINED WORKFLOWS 74
5.5 VALUE CHAIN ANALYSIS 74
5.6 PORTER’S FIVE FORCES ANALYSIS 76
5.6.1 BARGAINING POWER OF SUPPLIERS 77
5.6.2 BARGAINING POWER OF BUYERS 77
5.6.3 THREAT OF SUBSTITUTES 77
5.6.4 THREAT OF NEW ENTRANTS 77
5.6.5 INTENSITY OF COMPETITIVE RIVALRY 77
5.7 REGULATORY ANALYSIS 78
5.7.1 REGULATORY LANDSCAPE 78
5.7.1.1 North America 78
5.7.1.2 Europe 79
5.7.1.3 Asia Pacific 80
5.7.1.4 Latin America 81
5.7.1.5 Middle East & Africa 81
5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81
5.8 PATENT ANALYSIS 84
5.8.1 PATENT PUBLICATION TRENDS FOR AI IN BIOTECHNOLOGY 84
5.8.2 JURISDICTION AND TOP APPLICANT ANALYSIS 85
5.9 TECHNOLOGY ANALYSIS 89
5.9.1 KEY TECHNOLOGIES 89
5.9.1.1 Natural language processing (NLP) 89
5.9.1.2 Predictive analytics 89
5.9.2 COMPLEMENTARY TECHNOLOGIES 89
5.9.2.1 Cloud computing 89
5.9.2.2 Big data analytics 89
5.10 INDUSTRY TRENDS 90
5.10.1 EVOLUTION OF AI IN BIOTECHNOLOGY 90
5.10.2 COMPUTER-AIDED DRUG DESIGN AND AI 91
5.11 PRICING ANALYSIS 91
5.11.1 INDICATIVE PRICING ANALYSIS, BY DRUG DISCOVERY PROCESS 92
5.11.2 AVERAGE SELLING PRICE, BY REGION (QUALITATIVE) 92
5.12 KEY CONFERENCES & EVENTS, 2025–2026 92
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 94
5.13.1 BUYING CRITERIA 95
5.14 TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 96
5.15 END-USER ANALYSIS 97
5.15.1 UNMET NEEDS 97
5.15.2 END-USER EXPECTATIONS 98
5.16 INVESTMENT & FUNDING SCENARIO 98
5.17 IMPACT OF AI/GEN AI ON AI IN BIOTECHNOLOGY MARKET 99
5.17.1 KEY USE CASES 100
5.17.2 CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION 100
5.17.2.1 Case study: Accelerated biomarker discovery and clinical trial optimization 100
5.17.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 101
5.17.3.1 Drug discovery and development market 101
5.17.3.2 Genomics and bioinformatics market 101
5.17.3.3 Medical imaging & diagnostics market 102
5.17.4 USER READINESS & IMPACT ASSESSMENT 102
5.17.4.1 User readiness 102
5.17.4.1.1 Pharmaceutical companies 102
5.17.4.1.2 Biotechnology companies 102
5.17.4.2 Impact assessment 103
5.17.4.2.1 User A: Pharmaceutical companies 103
5.17.4.2.1.1 Implementation 103
5.17.4.2.1.2 Impact 103
5.17.4.2.2 User B: Biotechnology companies 103
5.17.4.2.2.1 Implementation 103
5.17.4.2.2.2 Impact 103
6 AI IN BIOTECHNOLOGY MARKET, BY OFFERING 104
6.1 INTRODUCTION 105
6.2 END-TO-END SOLUTIONS 105
6.2.1 GROWING USE OF ADVANCED ALGORITHMS TO IMPROVE PRECISION AND EFFICIENCY TO BOOST MARKET GROWTH 105
6.3 NICHE SOLUTIONS 106
6.3.1 ABILITY OF NICHE SOLUTIONS TO ADDRESS SPECIFIC CHALLENGES WITHIN DRUG DISCOVERY TO SUPPORT ADOPTION 106
6.4 TECHNOLOGIES 107
6.4.1 ABILITY OF TECHNOLOGIES TO ENHANCE DRUG DISCOVERY, PERSONALIZED MEDICINE, AND DATA ANALYTICS TO FUEL GROWTH 107
6.5 SERVICES 108
6.5.1 CONSULTING SERVICES 109
6.5.1.1 Increasing efficiency of research processes and cost savings to boost adoption of consulting services 109
6.5.2 IMPLEMENTATION SERVICES & ONGOING IT SUPPORT 110
6.5.2.1 Increasing precision and efficiency in IT support services to boost demand 110
6.5.3 TRAINING & EDUCATION SERVICES 110
6.5.3.1 Need for skilled talent to drive market growth 110
6.5.4 POST-SALES & MAINTENANCE SERVICES 111
6.5.4.1 Complexity of AI systems and need for improvement in AI algorithms to boost market 111
7 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION 113
7.1 INTRODUCTION 114
7.2 RESEARCH & DEVELOPMENT 114
7.2.1 DRUG DISCOVERY 116
7.2.1.1 Molecular design & optimization 117
7.2.1.1.1 Increased efficiency in drug discovery with molecular design & optimization to drive market growth 117
7.2.1.2 Biomarker discovery 118
7.2.1.2.1 Ability to analyze large data sets with AI-enabled biomarker discovery to boost demand for 118
7.2.1.3 Structure-activity relationship (SAR) modeling 119
7.2.1.3.1 Improved data analysis, predictive modeling, and compound optimization for drug candidates with SAR to fuel growth 119
7.2.2 CLINICAL DEVELOPMENT 119
7.2.2.1 Trial design 121
7.2.2.1.1 Ability of AI to improve trial design through simulations and patient stratification to favor market 121
7.2.2.2 Site selection 121
7.2.2.2.1 Optimized process of selecting clinical trial sites to fuel growth 121
7.2.2.3 Recruitment 122
7.2.2.3.1 Enhanced process of selecting and enrolling participants for clinical trials to drive demand 122
7.2.2.4 Clinical data assessment 123
7.2.2.4.1 Ability of clinical data assessment to enhance efficiency and accuracy of data interpretation to propel market 123
7.2.2.5 Predictive toxicity & risk monitoring 123
7.2.2.5.1 Ability of data integration and predictive modeling to create comprehensive risk profiles for drug candidates to support market 123
7.2.2.6 Monitoring & drug adherence 124
7.2.2.6.1 Enhanced patient compliance with monitoring & drug adherence to drive market growth 124
7.2.2.7 Real-world evidence (RWE) analysis 125
7.2.2.7.1 Enhanced safety monitoring & economic evaluation with RWE analysis to propel growth 125
7.3 REGULATORY COMPLIANCE 125
7.3.1 ABILITY OF AI TO ENSURE REGULATORY COMPLIANCE IN CLINICAL TRIALS TO SUPPORT GROWTH 125
7.4 MANUFACTURING & SUPPLY CHAIN 126
7.4.1 SUPPLY CHAIN PLANNING 128
7.4.1.1 Increasing demand for real-time data analytics to accelerate market growth 128
7.4.2 INVENTORY MANAGEMENT 128
7.4.2.1 Automating stock tracking and replenishment with advanced analytics to fuel growth 128
7.4.3 LOGISTICS OPTIMIZATION 129
7.4.3.1 Ability of AI to drive collaboration and transparency in biotechnology logistics to aid growth 129
7.4.4 DEMAND FORECASTING 130
7.4.4.1 Ability to integrate data for reliable demand forecasts to fuel growth 130
7.4.5 PREDICTIVE MAINTENANCE 130
7.4.5.1 Boosting equipment reliability with AI-powered predictive maintenance to drive demand 130
7.4.6 OTHER MANUFACTURING & SUPPLY CHAIN FUNCTIONS 131
7.5 LAUNCH & COMMERCIAL 132
7.5.1 LAUNCH COORDINATION 133
7.5.1.1 Growing product launch success rates through predictive analytics to boost adoption 133
7.5.2 PATIENT ENGAGEMENT 133
7.5.2.1 Advantages such as real-time patient feedback for better health outcomes to support growth 133
7.5.3 MARKETING OPERATIONS 134
7.5.3.1 Enhanced marketing performance with AI to boost market 134
7.5.4 PREDICTIVE PRICING 135
7.5.4.1 Ability of AI to enhance pricing accuracy to drive adoption 135
7.6 POST-MARKETING SURVEILLANCE & PATIENT SUPPORT 135
7.6.1 MEDICATION ADHERENCE 136
7.6.1.1 Growing demand for personalized healthcare to drive market 136
7.6.2 ADVERSE EVENT REPORTING 137
7.6.2.1 Advantages such as faster post-market surveillance and enhanced drug safety to drive demand 137
7.6.3 PATIENT MONITORING 138
7.6.3.1 Rise of remote healthcare solutions to boost demand 138
7.6.4 COMPLIANCE MONITORING 138
7.6.4.1 Increasing complexity of regulatory requirements to drive adoption 138
7.6.5 PATIENT SUPPORT PROGRAMS 139
7.6.5.1 Growing interest in patient-centered care to support growth 139
7.7 CORPORATE 140
7.7.1 RISK MANAGEMENT 141
7.7.1.1 Rising expenditure for drug development to support growth 141
7.7.2 COMPLIANCE MONITORING 141
7.7.2.1 Strict guidelines from bodies to aid growth 141
7.7.3 SALES FORCE OPTIMIZATION 142
7.7.3.1 Need for data-driven decision-making to boost adoption of sales force optimization 142
7.7.4 OTHER CORPORATE FUNCTIONS 143
8 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE 144
8.1 INTRODUCTION 145
8.2 CLOUD-BASED SOLUTIONS 145
8.2.1 PUBLIC CLOUD 146
8.2.1.1 Need to reduce dependency on expensive on-premise infrastructure to boost demand 146
8.2.2 PRIVATE CLOUD 147
8.2.2.1 Need for enhanced security and data protection to drive market growth 147
8.2.3 MULTI-CLOUD 148
8.2.3.1 Enhanced flexibility & cost optimization to support market growth 148
8.2.4 HYBRID CLOUD 149
8.2.4.1 Cost efficiency and flexibility of hybrid cloud to fuel growth 149
8.3 ON-PREMISE SOLUTIONS 150
8.3.1 ADVANTAGES SUCH AS DATA SECURITY AND PRIVACY AND COMPLIANCE WITH REGULATIONS TO FAVOR GROWTH 150
9 AI IN BIOTECHNOLOGY MARKET, BY END USER 152
9.1 INTRODUCTION 153
9.2 PHARMACEUTICAL COMPANIES 153
9.2.1 INNOVATION AND EFFICIENCY ASSOCIATED WITH AI INTEGRATION IN DRUG DISCOVERY & DEVELOPMENT TO BOOST ADOPTION 153
9.3 BIOTECHNOLOGY COMPANIES 154
9.3.1 ABILITY OF AI-DRIVEN INNOVATIONS TO ACCELERATE PERSONALIZED MEDICINE AND DRUG DISCOVERY TO SUPPORT GROWTH 154
9.4 RESEARCH INSTITUTES & LABS 155
9.4.1 STRATEGIC INVESTMENTS AND COLLABORATIONS TO PROPEL AI ADVANCEMENTS IN RESEARCH INSTITUTES AND LABS 155
9.5 HEALTHCARE PROVIDERS 156
9.5.1 IMPROVED PATIENT OUTCOMES TO SUPPORT ADOPTION 156
9.6 CONTRACT RESEARCH ORGANIZATIONS (CROS) 157
9.6.1 ABILITY OF AI TECHNOLOGIES TO ACCELERATE CLINICAL TRIALS AND IMPROVE PATIENT RECRUITMENT TO FUEL GROWTH 157
10 AI IN BIOTECHNOLOGY MARKET, BY REGION 159
10.1 INTRODUCTION 160
10.2 NORTH AMERICA 161
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 167
10.2.2 US 167
10.2.2.1 Increasing investments and partnerships to drive market 167
10.2.3 CANADA 173
10.2.3.1 Availability of advanced facilities and shorter approval times for drug candidates to drive market 173
10.3 EUROPE 179
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 186
10.3.2 GERMANY 186
10.3.2.1 Increased funding in start-ups to drive uptake of AI in biotechnology 186
10.3.3 UK 192
10.3.3.1 Increasing investments and government fund allocations to drive market 192
10.3.4 FRANCE 197
10.3.4.1 Government initiatives in France to support market growth 197
10.3.5 ITALY 203
10.3.5.1 Growing investments to create opportunities for market growth 203
10.3.6 SPAIN 209
10.3.6.1 Increasing need for personalized medicine and data-driven healthcare to increase adoption rate in market 209
10.3.7 REST OF EUROPE 214
10.4 ASIA PACIFIC 220
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 228
10.4.2 JAPAN 228
10.4.2.1 Accelerating AI-driven drug discovery and biotechnology innovation to drive market in Japan 228
10.4.3 CHINA 234
10.4.3.1 Rising foreign investments to drive market in China 234
10.4.4 INDIA 240
10.4.4.1 Increasing number of start-ups and support from government to propel market 240
10.4.5 SOUTH KOREA 246
10.4.5.1 Significant advances in AI integration for R&D to fuel growth 246
10.4.6 REST OF ASIA PACIFIC 252
10.5 LATIN AMERICA 258
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 264
10.5.2 BRAZIL 264
10.5.2.1 Funding of biotech companies to drive market in Brazil 264
10.5.3 MEXICO 270
10.5.3.1 Investment inflows and strengthening AI-related education to drive market in Mexico 270
10.5.4 REST OF LATIN AMERICA 276
10.6 MIDDLE EAST & AFRICA 282
10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 288
10.6.2 GCC COUNTRIES 288
10.6.2.1 Increase in healthcare investments to support market growth 288
10.6.3 REST OF MIDDLE EAST & AFRICA 295
11 COMPETITIVE LANDSCAPE 302
11.1 INTRODUCTION 302
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN 303
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AI IN BIOTECHNOLOGY MARKET 303
11.3 REVENUE ANALYSIS, 2019–2023 304
11.4 MARKET SHARE ANALYSIS, 2023 305
11.4.1 RANKING OF KEY MARKET PLAYERS 308
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 308
11.5.1 STARS 308
11.5.2 EMERGING LEADERS 308
11.5.3 PERVASIVE PLAYERS 309
11.5.4 PARTICIPANTS 309
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 310
11.5.5.1 Company footprint 310
11.5.5.2 Component footprint 311
11.5.5.3 Application footprint 312
11.5.5.4 End-user footprint 313
11.5.5.5 Region footprint 314
11.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023 315
11.6.1 PROGRESSIVE COMPANIES 315
11.6.2 RESPONSIVE COMPANIES 315
11.6.3 DYNAMIC COMPANIES 315
11.6.4 STARTING BLOCKS 315
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 317
11.7 COMPANY VALUATION & FINANCIAL METRICS 319
11.8 BRAND/PRODUCT COMPARISON 320
11.9 COMPETITIVE SCENARIO 321
11.9.1 PRODUCT LAUNCHES & UPGRADES 321
11.9.2 DEALS 322
11.9.3 EXPANSIONS 324
12 COMPANY PROFILES 325
12.1 KEY PLAYERS 325
12.1.1 NVIDIA CORPORATION 325
12.1.1.1 Business overview 325
12.1.1.2 Products offered 326
12.1.1.3 Recent developments 327
12.1.1.3.1 Product launches 327
12.1.1.3.2 Deals 327
12.1.1.4 MnM view 328
12.1.1.4.1 Right to win 328
12.1.1.4.2 Strategic choices 328
12.1.1.4.3 Weaknesses & competitive threats 328
12.1.2 ILLUMINA, INC. 329
12.1.2.1 Business overview 329
12.1.2.2 Products offered 330
12.1.2.3 Recent developments 331
12.1.2.3.1 Product launches 331
12.1.2.3.2 Deals 332
12.1.2.4 MnM view 333
12.1.2.4.1 Right to win 333
12.1.2.4.2 Strategic choices 334
12.1.2.4.3 Weaknesses & competitive threats 334
12.1.3 EXSCIENTIA 335
12.1.3.1 Business overview 335
12.1.3.2 Products offered 336
12.1.3.3 Recent developments 336
12.1.3.3.1 Product launches 336
12.1.3.3.2 Deals 336
12.1.3.3.3 Other developments 339
12.1.3.4 MnM view 340
12.1.3.4.1 Right to win 340
12.1.3.4.2 Strategic choices 340
12.1.3.4.3 Weaknesses & competitive threats 340
12.1.4 SCHRÖDINGER, INC. 341
12.1.4.1 Business overview 341
12.1.4.2 Products offered 342
12.1.4.3 Recent developments 343
12.1.4.3.1 Product upgrades 343
12.1.4.3.2 Deals 343
12.1.5 RECURSION PHARMACEUTICALS, INC. 345
12.1.5.1 Business overview 345
12.1.5.2 Products offered 346
12.1.5.3 Recent developments 346
12.1.5.3.1 Deals 346
12.1.5.3.2 Expansions 347
12.1.5.3.3 Other developments 347
12.1.6 SOPHIA GENETICS 348
12.1.6.1 Business overview 348
12.1.6.2 Products offered 349
12.1.6.3 Recent developments 349
12.1.6.3.1 Product launches 349
12.1.6.3.2 Deals 350
12.1.7 PREDICTIVE ONCOLOGY 352
12.1.7.1 Business overview 352
12.1.7.2 Products offered 353
12.1.7.3 Recent developments 353
12.1.7.3.1 Product launches 353
12.1.7.3.2 Deals 353
12.1.7.3.3 Expansions 354
12.1.8 BENEVOLENTAI 355
12.1.8.1 Business overview 355
12.1.8.2 Products offered 356
12.1.8.3 Recent developments 356
12.1.8.3.1 Deals 356
12.1.8.3.2 Other developments 357
12.1.9 EUROFINS DISCOVERY 358
12.1.9.1 Business overview 358
12.1.9.2 Products offered 359
12.1.9.3 Recent developments 359
12.1.9.3.1 Product launches 359
12.1.9.3.2 Deals 360
12.1.9.3.3 Expansions 361
12.1.10 XTALPI INC. 362
12.1.10.1 Business overview 362
12.1.10.2 Products offered 363
12.1.10.3 Recent developments 363
12.1.10.3.1 Deals 363
12.1.11 DNANEXUS, INC. 365
12.1.11.1 Business overview 365
12.1.11.2 Products offered 365
12.1.11.3 Recent developments 366
12.1.11.3.1 Deals 366
12.1.11.3.2 Other developments 368
12.1.12 NUMEDII, INC. 369
12.1.12.1 Business overview 369
12.1.12.2 Products offered 369
12.1.13 BPGBIO, INC. 370
12.1.13.1 Business overview 370
12.1.13.2 Products offered 370
12.1.13.3 Recent developments 371
12.1.13.3.1 Product launches 371
12.1.13.3.2 Deals 371
12.1.13.3.3 Other developments 372
12.1.14 IKTOS 373
12.1.14.1 Business overview 373
12.1.14.2 Products offered 373
12.1.14.3 Recent developments 374
12.1.14.3.1 Deals 374
12.1.14.3.2 Other developments 374
12.1.15 INSILICO MEDICINE 375
12.1.15.1 Business overview 375
12.1.15.2 Products offered 375
12.1.15.3 Recent developments 376
12.1.15.3.1 Product approvals 376
12.1.15.3.2 Deals 376
12.1.15.3.3 Other developments 376
12.1.16 LOGICA (CHARLES RIVER + VALO HEALTH) 377
12.1.16.1 Business overview 377
12.1.16.2 Products offered 377
12.1.16.3 Recent developments 378
12.1.16.3.1 Product launches 378
12.1.17 AMERICAN CHEMICAL SOCIETY 379
12.1.17.1 Business overview 379
12.1.17.2 Products offered 379
12.1.18 AGANITHA AI INC. 380
12.1.18.1 Business overview 380
12.1.18.2 Products offered 380
12.1.18.3 Recent developments 381
12.1.18.3.1 Deals 381
12.1.18.3.2 Other developments 381
12.2 START-UP/SME PLAYERS 382
12.2.1 VERISIM LIFE 382
12.2.2 VALO HEALTH 382
12.2.3 TEMPUS AI, INC. 383
12.2.4 LIFEBIT BIOTECH LTD. 384
12.2.5 GENOOX 384
12.2.6 DATA4CURE, INC. 385
12.2.7 DEEP GENOMICS 385
13 APPENDIX 386
13.1 DISCUSSION GUIDE 386
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 393
13.3 CUSTOMIZATION OPTIONS 395
13.4 RELATED REPORTS 395
13.5 AUTHOR DETAILS 396
LIST OF TABLES
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 41
TABLE 2 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS IN AI IN BIOTECHNOLOGY MARKET (2021−2025) 65
TABLE 3 AI IN BIOTECHNOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS 76
TABLE 4 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 81
TABLE 5 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 82
TABLE 6 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 82
TABLE 7 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 83
TABLE 8 LIST OF PATENTS/PATENT APPLICATIONS IN AI IN BIOTECHNOLOGY MARKET, 2021–2024 86
TABLE 9 AI IN BIOTECHNOLOGY MARKET: INDICATIVE PRICING, BY DRUG DISCOVERY PROCESS 92
TABLE 10 AI IN BIOTECHNOLOGY MARKET: KEY CONFERENCES & EVENTS, 2025–2026 92
TABLE 11 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP 3 END USERS (%) 94
TABLE 12 KEY BUYING CRITERIA FOR TOP 3 END USERS 95
TABLE 13 UNMET NEEDS IN AI IN BIOTECHNOLOGY MARKET 97
TABLE 14 END-USER EXPECTATIONS IN AI IN BIOTECHNOLOGY MARKET 98
TABLE 15 AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 105
TABLE 16 AI IN BIOTECHNOLOGY MARKET FOR END-TO-END SOLUTIONS, BY REGION,
2022–2029 (USD MILLION) 106
TABLE 17 AI IN BIOTECHNOLOGY MARKET FOR NICHE SOLUTIONS, BY REGION,
2022–2029 (USD MILLION) 107
TABLE 18 AI IN BIOTECHNOLOGY MARKET FOR TECHNOLOGIES, BY REGION,
2022–2029 (USD MILLION) 108
TABLE 19 AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 108
TABLE 20 AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY REGION,
2022–2029 (USD MILLION) 109
TABLE 21 AI IN BIOTECHNOLOGY MARKET FOR CONSULTING SERVICES, BY REGION,
2022–2029 (USD MILLION) 109
TABLE 22 AI IN BIOTECHNOLOGY MARKET FOR IMPLEMENTATION SERVICES & ONGOING IT SUPPORT, BY REGION, 2022–2029 (USD MILLION) 110
TABLE 23 AI IN BIOTECHNOLOGY MARKET FOR TRAINING & EDUCATION SERVICES,
BY REGION, 2022–2029 (USD MILLION) 111
TABLE 24 AI IN BIOTECHNOLOGY MARKET FOR POST-SALES & MAINTENANCE SERVICES,
BY REGION, 2022–2029 (USD MILLION) 112
TABLE 25 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 114
TABLE 26 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS,
BY TYPE, 2022–2029 (USD MILLION) 115
TABLE 27 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS,
BY REGION, 2022–2029 (USD MILLION) 116
TABLE 28 EXAMPLES OF AI TOOLS USED IN DRUG DISCOVERY 116
TABLE 29 AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,
2022–2029 (USD MILLION) 117
TABLE 30 AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY REGION,
2022–2029 (USD MILLION) 117
TABLE 31 AI IN BIOTECHNOLOGY MARKET FOR MOLECULAR DESIGN & OPTIMIZATION,
BY REGION, 2022–2029 (USD MILLION) 118
TABLE 32 AI IN BIOTECHNOLOGY MARKET FOR BIOMARKER DISCOVERY, BY REGION,
2022–2029 (USD MILLION) 118
TABLE 33 AI IN BIOTECHNOLOGY MARKET FOR STRUCTURE-ACTIVITY RELATIONSHIP (SAR) MODELING, BY REGION, 2022–2029 (USD MILLION) 119
TABLE 34 AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE,
2022–2029 (USD MILLION) 120
TABLE 35 AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY REGION,
2022–2029 (USD MILLION) 120
TABLE 36 AI IN BIOTECHNOLOGY MARKET FOR TRIAL DESIGN, BY REGION,
2022–2029 (USD MILLION) 121
TABLE 37 AI IN BIOTECHNOLOGY MARKET FOR SITE SELECTION, BY REGION,
2022–2029 (USD MILLION) 122
TABLE 38 AI IN BIOTECHNOLOGY MARKET FOR RECRUITMENT, BY REGION,
2022–2029 (USD MILLION) 122
TABLE 39 AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DATA ASSESSMENT, BY REGION, 2022–2029 (USD MILLION) 123
TABLE 40 AI IN BIOTECHNOLOGY MARKET FOR PREDICTIVE TOXICITY & RISK MONITORING, BY REGION, 2022–2029 (USD MILLION) 124
TABLE 41 AI IN BIOTECHNOLOGY MARKET FOR MONITORING & DRUG ADHERENCE,
BY REGION, 2022–2029 (USD MILLION) 124
TABLE 42 AI IN BIOTECHNOLOGY MARKET FOR REAL-WORLD EVIDENCE (RWE) ANALYSIS,
BY REGION, 2022–2029 (USD MILLION) 125
TABLE 43 AI IN BIOTECHNOLOGY MARKET FOR REGULATORY COMPLIANCE FUNCTIONS,
BY REGION, 2022–2029 (USD MILLION) 126
TABLE 44 AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 127
TABLE 45 AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY REGION, 2022–2029 (USD MILLION) 127
TABLE 46 AI IN BIOTECHNOLOGY MARKET FOR SUPPLY CHAIN PLANNING, BY REGION, 2022–2029 (USD MILLION) 128
TABLE 47 AI IN BIOTECHNOLOGY MARKET FOR INVENTORY MANAGEMENT, BY REGION, 2022–2029 (USD MILLION) 129
TABLE 48 AI IN BIOTECHNOLOGY MARKET FOR LOGISTICS OPTIMIZATION, BY REGION,
2022–2029 (USD MILLION) 129
TABLE 49 AI IN BIOTECHNOLOGY MARKET FOR DEMAND FORECASTING, BY REGION,
2022–2029 (USD MILLION) 130
TABLE 50 AI IN BIOTECHNOLOGY MARKET FOR PREDICTIVE MAINTENANCE, BY REGION, 2022–2029 (USD MILLION) 131
TABLE 51 AI IN BIOTECHNOLOGY MARKET FOR OTHER MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY REGION, 2022–2029 (USD MILLION) 131
TABLE 52 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS,
BY TYPE, 2022–2029 (USD MILLION) 132
TABLE 53 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS,
BY REGION, 2022–2029 (USD MILLION) 132
TABLE 54 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH COORDINATION, BY REGION,
2022–2029 (USD MILLION) 133
TABLE 55 AI IN BIOTECHNOLOGY MARKET FOR PATIENT ENGAGEMENT, BY REGION,
2022–2029 (USD MILLION) 134
TABLE 56 AI IN BIOTECHNOLOGY MARKET FOR MARKETING OPERATIONS, BY REGION, 2022–2029 (USD MILLION) 134
TABLE 57 AI IN BIOTECHNOLOGY MARKET FOR PREDICTIVE PRICING, BY REGION,
2022–2029 (USD MILLION) 135
TABLE 58 AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 136
TABLE 59 AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY REGION, 2022–2029 (USD MILLION) 136
TABLE 60 AI IN BIOTECHNOLOGY MARKET FOR MEDICATION ADHERENCE, BY REGION, 2022–2029 (USD MILLION) 137
TABLE 61 AI IN BIOTECHNOLOGY MARKET FOR ADVERSE EVENT REPORTING, BY REGION, 2022–2029 (USD MILLION) 137
TABLE 62 AI IN BIOTECHNOLOGY MARKET FOR PATIENT MONITORING, BY REGION,
2022–2029 (USD MILLION) 138
TABLE 63 AI IN BIOTECHNOLOGY MARKET FOR COMPLIANCE MONITORING, BY REGION, 2022–2029 (USD MILLION) 139
TABLE 64 AI IN BIOTECHNOLOGY MARKET FOR PATIENT SUPPORT PROGRAMS, BY REGION, 2022–2029 (USD MILLION) 139
TABLE 65 AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE,
2022–2029 (USD MILLION) 140
TABLE 66 AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY REGION,
2022–2029 (USD MILLION) 140
TABLE 67 AI IN BIOTECHNOLOGY MARKET FOR RISK MANAGEMENT, BY REGION,
2022–2029 (USD MILLION) 141
TABLE 68 AI IN BIOTECHNOLOGY MARKET FOR COMPLIANCE MONITORING, BY REGION, 2022–2029 (USD MILLION) 142
TABLE 69 AI IN BIOTECHNOLOGY MARKET FOR SALES FORCE OPTIMIZATION, BY REGION, 2022–2029 (USD MILLION) 142
TABLE 70 AI IN BIOTECHNOLOGY MARKET FOR OTHER CORPORATE FUNCTIONS, BY REGION, 2022–2029 (USD MILLION) 143
TABLE 71 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 145
TABLE 72 AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE,
2022–2029 (USD MILLION) 145
TABLE 73 AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY REGION, 2022–2029 (USD MILLION) 146
TABLE 74 AI IN BIOTECHNOLOGY MARKET FOR PUBLIC CLOUD, BY REGION,
2022–2029 (USD MILLION) 147
TABLE 75 AI IN BIOTECHNOLOGY MARKET FOR PRIVATE CLOUD, BY REGION,
2022–2029 (USD MILLION) 148
TABLE 76 AI IN BIOTECHNOLOGY MARKET FOR MULTI-CLOUD, BY REGION,
2022–2029 (USD MILLION) 149
TABLE 77 AI IN BIOTECHNOLOGY MARKET FOR HYBRID CLOUD, BY REGION,
2022–2029 (USD MILLION) 150
TABLE 78 AI IN BIOTECHNOLOGY MARKET FOR ON-PREMISE SOLUTIONS, BY REGION,
2022–2029 (USD MILLION) 151
TABLE 79 AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 153
TABLE 80 AI IN BIOTECHNOLOGY MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD MILLION) 154
TABLE 81 AI IN BIOTECHNOLOGY MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION) 155
TABLE 82 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH INSTITUTES & LABS, BY REGION, 2022–2029 (USD MILLION) 156
TABLE 83 AI IN BIOTECHNOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2022–2029 (USD MILLION) 157
TABLE 84 AI IN BIOTECHNOLOGY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2022–2029 (USD MILLION) 158
TABLE 85 AI IN BIOTECHNOLOGY MARKET, BY REGION, 2022–2029 (USD MILLION) 160
TABLE 86 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 162
TABLE 87 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 162
TABLE 88 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 162
TABLE 89 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 163
TABLE 90 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 163
TABLE 91 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY,
BY TYPE, 2022–2029 (USD MILLION) 163
TABLE 92 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 164
TABLE 93 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 164
TABLE 94 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 165
TABLE 95 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE,
2022–2029 (USD MILLION) 165
TABLE 96 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 166
TABLE 97 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION) 166
TABLE 98 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 166
TABLE 99 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 167
TABLE 100 US: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 168
TABLE 101 US: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 168
TABLE 102 US: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 169
TABLE 103 US: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 169
TABLE 104 US: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,
2022–2029 (USD MILLION) 169
TABLE 105 US: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 170
TABLE 106 US: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 170
TABLE 107 US: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS,
BY TYPE, 2022–2029 (USD MILLION) 171
TABLE 108 US: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 171
TABLE 109 US: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 172
TABLE 110 US: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 172
TABLE 111 US: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 172
TABLE 112 US: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 173
TABLE 113 CANADA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 174
TABLE 114 CANADA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 174
TABLE 115 CANADA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 175
TABLE 116 CANADA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 175
TABLE 117 CANADA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,
2022–2029 (USD MILLION) 175
TABLE 118 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 176
TABLE 119 CANADA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 176
TABLE 120 CANADA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 177
TABLE 121 CANADA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 177
TABLE 122 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 178
TABLE 123 CANADA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 178
TABLE 124 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,
BY TYPE, 2022–2029 (USD MILLION) 178
TABLE 125 CANADA: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 179
TABLE 126 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 180
TABLE 127 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 180
TABLE 128 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 181
TABLE 129 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 181
TABLE 130 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 182
TABLE 131 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,
2022–2029 (USD MILLION) 182
TABLE 132 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 183
TABLE 133 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 183
TABLE 134 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 184
TABLE 135 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 184
TABLE 136 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS,
BY TYPE, 2022–2029 (USD MILLION) 185
TABLE 137 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 185
TABLE 138 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,
BY TYPE, 2022–2029 (USD MILLION) 185
TABLE 139 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 186
TABLE 140 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 187
TABLE 141 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 187
TABLE 142 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 188
TABLE 143 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 188
TABLE 144 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION) 188
TABLE 145 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT,
BY TYPE, 2022–2029 (USD MILLION) 189
TABLE 146 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 189
TABLE 147 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 190
TABLE 148 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 190
TABLE 149 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 191
TABLE 150 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 191
TABLE 151 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,
BY TYPE, 2022–2029 (USD MILLION) 191
TABLE 152 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 192
TABLE 153 UK: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 192
TABLE 154 UK: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 193
TABLE 155 UK: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 193
TABLE 156 UK: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 193
TABLE 157 UK: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,
2022–2029 (USD MILLION) 194
TABLE 158 UK: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 194
TABLE 159 UK: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 195
TABLE 160 UK: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS,
BY TYPE, 2022–2029 (USD MILLION) 195
TABLE 161 UK: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 196
TABLE 162 UK: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 196
TABLE 163 UK: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 196
TABLE 164 UK: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 197
TABLE 165 UK: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 197
TABLE 166 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 198
TABLE 167 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 198
TABLE 168 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 199
TABLE 169 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 199
TABLE 170 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,
2022–2029 (USD MILLION) 199
TABLE 171 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 200
TABLE 172 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 200
TABLE 173 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 201
TABLE 174 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 201
TABLE 175 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 202
TABLE 176 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 202
TABLE 177 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 202
TABLE 178 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 203
TABLE 179 ITALY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 204
TABLE 180 ITALY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION) 204
TABLE 181 ITALY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 205
TABLE 182 ITALY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 205
TABLE 183 ITALY: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION) 205
TABLE 184 ITALY: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 206
TABLE 185 ITALY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 206
TABLE 186 ITALY: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 207
TABLE 187 ITALY: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 207
TABLE 188 ITALY: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 208
TABLE 189 ITALY: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION) 208
TABLE 190 ITALY: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 208
TABLE 191 ITALY: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 209
TABLE 192 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 209
TABLE 193 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 210
TABLE 194 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 210
TABLE 195 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 211
TABLE 196 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,
2022–2029 (USD MILLION) 211
TABLE 197 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 211
TABLE 198 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 212
TABLE 199 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 212
TABLE 200 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 213
TABLE 201 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 213
TABLE 202 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 213
TABLE 203 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 214
TABLE 204 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 214
TABLE 205 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 215
TABLE 206 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION) 215
TABLE 207 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 216
TABLE 208 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 216
TABLE 209 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY,
BY TYPE, 2022–2029 (USD MILLION) 216
TABLE 210 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 217
TABLE 211 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 217
TABLE 212 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 218
TABLE 213 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE,
2022–2029 (USD MILLION) 218
TABLE 214 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 219
TABLE 215 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION) 219
TABLE 216 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 219
TABLE 217 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 220
TABLE 218 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 222
TABLE 219 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 222
TABLE 220 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 223
TABLE 221 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 223
TABLE 222 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 224
TABLE 223 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION) 224
TABLE 224 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT,
BY TYPE, 2022–2029 (USD MILLION) 225
TABLE 225 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 225
TABLE 226 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 226
TABLE 227 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE,
2022–2029 (USD MILLION) 226
TABLE 228 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS,
BY TYPE, 2022–2029 (USD MILLION) 227
TABLE 229 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 227
TABLE 230 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,
BY TYPE, 2022–2029 (USD MILLION) 227
TABLE 231 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 228
TABLE 232 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 229
TABLE 233 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 229
TABLE 234 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 230
TABLE 235 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 230
TABLE 236 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,
2022–2029 (USD MILLION) 230
TABLE 237 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 231
TABLE 238 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 231
TABLE 239 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 232
TABLE 240 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 232
TABLE 241 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 233
TABLE 242 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 233
TABLE 243 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 233
TABLE 244 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 234
TABLE 245 CHINA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 235
TABLE 246 CHINA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 235
TABLE 247 CHINA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 236
TABLE 248 CHINA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 236
TABLE 249 CHINA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,
2022–2029 (USD MILLION) 236
TABLE 250 CHINA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 237
TABLE 251 CHINA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 237
TABLE 252 CHINA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 238
TABLE 253 CHINA: AI IN BIOTECHNOLOGY MARKET, BY POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 238
TABLE 254 CHINA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 239
TABLE 255 CHINA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 239
TABLE 256 CHINA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 239
TABLE 257 CHINA: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 240
TABLE 258 INDIA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 241
TABLE 259 INDIA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 241
TABLE 260 INDIA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 242
TABLE 261 INDIA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 242
TABLE 262 INDIA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,
2022–2029 (USD MILLION) 242
TABLE 263 INDIA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 243
TABLE 264 INDIA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 243
TABLE 265 INDIA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 244
TABLE 266 INDIA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 244
TABLE 267 INDIA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 245
TABLE 268 INDIA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 245
TABLE 269 INDIA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 245
TABLE 270 INDIA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 246
TABLE 271 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 247
TABLE 272 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 247
TABLE 273 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 248
TABLE 274 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 248
TABLE 275 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION) 248
TABLE 276 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT,
BY TYPE, 2022–2029 (USD MILLION) 249
TABLE 277 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING &
SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 249
TABLE 278 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 250
TABLE 279 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE,
2022–2029 (USD MILLION) 250
TABLE 280 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS,
BY TYPE, 2022–2029 (USD MILLION) 251
TABLE 281 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION) 251
TABLE 282 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 251
TABLE 283 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 252
TABLE 284 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 253
TABLE 285 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION) 253
TABLE 286 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 254
TABLE 287 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 254
TABLE 288 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY,
BY TYPE, 2022–2029 (USD MILLION) 254
TABLE 289 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 255
TABLE 290 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 255
TABLE 291 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 256
TABLE 292 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE,
2022–2029 (USD MILLION) 256
TABLE 293 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 257
TABLE 294 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION) 257
TABLE 295 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 257
TABLE 296 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 258
TABLE 297 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 259
TABLE 298 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 259
TABLE 299 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 259
TABLE 300 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 260
TABLE 301 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 260
TABLE 302 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION) 260
TABLE 303 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT,
BY TYPE, 2022–2029 (USD MILLION) 261
TABLE 304 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING &
SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 261
TABLE 305 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 262
TABLE 306 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE,
2022–2029 (USD MILLION) 262
TABLE 307 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS,
BY TYPE, 2022–2029 (USD MILLION) 263
TABLE 308 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 263
TABLE 309 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 263
TABLE 310 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 264
TABLE 311 BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 265
TABLE 312 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 265
TABLE 313 BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 266
TABLE 314 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 266
TABLE 315 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,
2022–2029 (USD MILLION) 266
TABLE 316 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 267
TABLE 317 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 267
TABLE 318 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 268
TABLE 319 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 268
TABLE 320 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 269
TABLE 321 BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 269
TABLE 322 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 269
TABLE 323 BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 270
TABLE 324 MEXICO: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 271
TABLE 325 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 271
TABLE 326 MEXICO: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 272
TABLE 327 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 272
TABLE 328 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,
2022–2029 (USD MILLION) 272
TABLE 329 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 273
TABLE 330 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 273
TABLE 331 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 274
TABLE 332 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 274
TABLE 333 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 275
TABLE 334 MEXICO: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 275
TABLE 335 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 275
TABLE 336 MEXICO: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 276
TABLE 337 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 277
TABLE 338 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION) 277
TABLE 339 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 278
TABLE 340 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 278
TABLE 341 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION) 278
TABLE 342 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 279
TABLE 343 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 279
TABLE 344 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 280
TABLE 345 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE,
2022–2029 (USD MILLION) 280
TABLE 346 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 281
TABLE 347 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION) 281
TABLE 348 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 281
TABLE 349 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 282
TABLE 350 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 283
TABLE 351 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 283
TABLE 352 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION) 283
TABLE 353 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 284
TABLE 354 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH
& DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 284
TABLE 355 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION) 284
TABLE 356 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 285
TABLE 357 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING
& SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 285
TABLE 358 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH
& COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 286
TABLE 359 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE,
2022–2029 (USD MILLION) 286
TABLE 360 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 287
TABLE 361 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION) 287
TABLE 362 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 287
TABLE 363 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 288
TABLE 364 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY OFFERING,
2022–2029 (USD MILLION) 290
TABLE 365 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE,
2022–2029 (USD MILLION) 290
TABLE 366 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,
2022–2029 (USD MILLION) 291
TABLE 367 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 291
TABLE 368 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY,
BY TYPE, 2022–2029 (USD MILLION) 291
TABLE 369 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 292
TABLE 370 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 292
TABLE 371 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 293
TABLE 372 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE,
2022–2029 (USD MILLION) 293
TABLE 373 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 294
TABLE 374 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2022–2029 (USD MILLION) 294
TABLE 375 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 294
TABLE 376 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY END USER,
2022–2029 (USD MILLION) 295
TABLE 377 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 296
TABLE 378 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION) 296
TABLE 379 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 297
TABLE 380 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 297
TABLE 381 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION) 297
TABLE 382 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 298
TABLE 383 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE,
2022–2029 (USD MILLION) 298
TABLE 384 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 299
TABLE 385 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE,
2022–2029 (USD MILLION) 299
TABLE 386 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET
FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 300
TABLE 387 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET,
BY DEPLOYMENT MODE, 2022–2029 (USD MILLION) 300
TABLE 388 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET
FOR CLOUD-BASED SOLUTIONS MODE, BY TYPE, 2022–2029 (USD MILLION) 300
TABLE 389 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET,
BY END USER, 2022–2029 (USD MILLION) 301
TABLE 390 AI IN BIOTECHNOLOGY: DEGREE OF COMPETITION 306
TABLE 391 AI IN BIOTECHNOLOGY MARKET: OFFERING FOOTPRINT 311
TABLE 392 AI IN BIOTECHNOLOGY MARKET: FUNCTION FOOTPRINT 312
TABLE 393 AI IN BIOTECHNOLOGY MARKET: END-USER FOOTPRINT 313
TABLE 394 AI IN BIOTECHNOLOGY: REGION FOOTPRINT 314
TABLE 395 AI IN BIOTECHNOLOGY MARKET: DETAILED LIST OF KEY START-UPS/SMES 317
TABLE 396 AI IN BIOTECHNOLOGY: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS 318
TABLE 397 AI IN BIOTECHNOLOGY MARKET: PRODUCT LAUNCHES & UPGRADES,
JANUARY 2021–JANUARY 2025 321
TABLE 398 AI IN BIOTECHNOLOGY MARKET: DEALS, JANUARY 2021–JANUARY 2025 322
TABLE 399 AI IN BIOTECHNOLOGY MARKET: EXPANSIONS, JANUARY 2021–JANUARY 2025 324
TABLE 400 NVIDIA CORPORATION: COMPANY OVERVIEW 325
TABLE 401 NVIDIA CORPORATION: PRODUCTS OFFERED 326
TABLE 402 NVIDIA CORPORATION: PRODUCT LAUNCHES, JANUARY 2021−JANUARY 2025 327
TABLE 403 NVIDIA CORPORATION: DEALS, JANUARY 2021−JANUARY 2025 327
TABLE 404 ILLUMINA, INC.: COMPANY OVERVIEW 329
TABLE 405 ILLUMINA, INC.: PRODUCTS OFFERED 330
TABLE 406 ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2021−JANUARY 2025 331
TABLE 407 ILLUMINA, INC.: DEALS, JANUARY 2021−JANUARY 2025 332
TABLE 408 EXSCIENTIA: COMPANY OVERVIEW 335
TABLE 409 EXSCIENTIA: PRODUCTS OFFERED 336
TABLE 410 EXSCIENTIA: PRODUCT LAUNCHES, JANUARY 2021−JANUARY 2025 336
TABLE 411 EXSCIENTIA: DEALS, JANUARY 2021−JANUARY 2025 336
TABLE 412 EXSCIENTIA: OTHER DEVELOPMENTS, JANUARY 2021−JANUARY 2025 339
TABLE 413 SCHRÖDINGER, INC.: COMPANY OVERVIEW 341
TABLE 414 SCHRÖDINGER, INC.: PRODUCTS OFFERED 342
TABLE 415 SCHRÖDINGER, INC.: PRODUCT UPGRADES, JANUARY 2021−JANUARY 2025 343
TABLE 416 SCHRÖDINGER, INC.: DEALS, JANUARY 2021−JANUARY 2025 343
TABLE 417 RECURSION PHARMACEUTICALS, INC.: COMPANY OVERVIEW 345
TABLE 418 RECURSION PHARMACEUTICALS, INC.: PRODUCTS OFFERED 346
TABLE 419 RECURSION PHARMACEUTICALS, INC.: DEALS, JANUARY 2021−JANUARY 2025 346
TABLE 420 RECURSION PHARMACEUTICALS, INC.: EXPANSIONS,
JANUARY 2021−JANUARY 2025 347
TABLE 421 RECURSION PHARMACEUTICALS, INC.: OTHER DEVELOPMENTS, JANUARY 2021−JANUARY 2025 347
TABLE 422 SOPHIA GENETICS: COMPANY OVERVIEW 348
TABLE 423 SOPHIA GENETICS: PRODUCTS OFFERED 349
TABLE 424 SOPHIA GENETICS: PRODUCT LAUNCHES, JANUARY 2021−JANUARY 2025 349
TABLE 425 SOPHIA GENETICS: DEALS, JANUARY 2021−JANUARY 2025 350
TABLE 426 PREDICTIVE ONCOLOGY: COMPANY OVERVIEW 352
TABLE 427 PREDICTIVE ONCOLOGY: PRODUCTS OFFERED 353
TABLE 428 PREDICTIVE ONCOLOGY: PRODUCT LAUNCHES, JANUARY 2021−JANUARY 2025 353
TABLE 429 PREDICTIVE ONCOLOGY: DEALS, JANUARY 2021−JANUARY 2025 353
TABLE 430 PREDICTIVE ONCOLOGY: EXPANSIONS, JANUARY 2021−JANUARY 2025 354
TABLE 431 BENEVOLENTAI: COMPANY OVERVIEW 355
TABLE 432 BENEVOLENTAI: PRODUCTS OFFERED 356
TABLE 433 BENEVOLENTAI: DEALS, JANUARY 2021−JANUARY 2025 356
TABLE 434 BENEVOLENTAI: OTHER DEVELOPMENTS, JANUARY 2021−JANUARY 2025 357
TABLE 435 EUROFINS DISCOVERY: COMPANY OVERVIEW 358
TABLE 436 EUROFINS DISCOVERY: PRODUCTS OFFERED 359
TABLE 437 EUROFINS DISCOVERY: PRODUCT LAUNCHES, JANUARY 2021−JANUARY 2025 359
TABLE 438 EUROFINS DISCOVERY: DEALS, JANUARY 2021−JANUARY 2025 360
TABLE 439 EUROFINS DISCOVERY: EXPANSIONS, JANUARY 2021−JANUARY 2025 361
TABLE 440 XTALPI INC.: COMPANY OVERVIEW 362
TABLE 441 XTALPI INC.: PRODUCTS OFFERED 363
TABLE 442 XTALPI INC.: DEALS, JANUARY 2021−JANUARY 2025 363
TABLE 443 DNANEXUS, INC.: COMPANY OVERVIEW 365
TABLE 444 DNANEXUS, INC.: PRODUCTS OFFERED 365
TABLE 445 DNANEXUS, INC.: DEALS, JANUARY 2021−JANUARY 2025 366
TABLE 446 DNANEXUS, INC.: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025 368
TABLE 447 NUMEDII, INC.: COMPANY OVERVIEW 369
TABLE 448 NUMEDII, INC.: PRODUCTS OFFERED 369
TABLE 449 BPGBIO, INC.: COMPANY OVERVIEW 370
TABLE 450 BPGBIO, INC.: PRODUCTS OFFERED 370
TABLE 451 BPGBIO, INC.: PRODUCT LAUNCHES, JANUARY 2021−JANUARY 2025 371
TABLE 452 BPGBIO, INC.: DEALS, JANUARY 2021−JANUARY 2025 371
TABLE 453 BPGBIO, INC.: OTHER DEVELOPMENTS, JANUARY 2021−JANUARY 2025 372
TABLE 454 IKTOS: COMPANY OVERVIEW 373
TABLE 455 IKTOS: PRODUCTS OFFERED 373
TABLE 456 IKTOS: DEALS, JANUARY 2021−JANUARY 2025 374
TABLE 457 IKTOS: OTHER DEVELOPMENTS, JANUARY 2021−JANUARY 2025 374
TABLE 458 INSILICO MEDICINE: COMPANY OVERVIEW 375
TABLE 459 INSILICO MEDICINE: PRODUCTS OFFERED 375
TABLE 460 INSILICO MEDICINE: PRODUCT APPROVALS, JANUARY 2021−JANUARY 2025 376
TABLE 461 INSILICO MEDICINE: DEALS, JANUARY 2021−JANUARY 2025 376
TABLE 462 INSILICO MEDICINE: OTHER DEVELOPMENTS, JANUARY 2021−JANUARY 2025 376
TABLE 463 LOGICA: COMPANY OVERVIEW 377
TABLE 464 LOGICA: PRODUCTS OFFERED 377
TABLE 465 LOGICA: PRODUCT LAUNCHES, JANUARY 2021−JANUARY 205 378
TABLE 466 AMERICAN CHEMICAL SOCIETY: COMPANY OVERVIEW 379
TABLE 467 AMERICAN CHEMICAL SOCIETY: PRODUCTS OFFERED 379
TABLE 468 AGANITHA AI INC.: COMPANY OVERVIEW 380
TABLE 469 AGANITHA AI INC.: PRODUCTS OFFERED 380
TABLE 470 AGANITHA AI INC.: DEALS, JANUARY 2021−JANUARY 2025 381
TABLE 471 AGANITHA AI INC.: OTHER DEVELOPMENTS, JANUARY 2021−JANUARY 2025 381
LIST OF FIGURES
FIGURE 1 AI IN BIOTECHNOLOGY MARKET SEGMENTATION & REGIONAL SCOPE 38
FIGURE 2 RESEARCH DESIGN 43
FIGURE 3 PRIMARY SOURCES 46
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 48
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 49
FIGURE 6 TOP-DOWN APPROACH 50
FIGURE 7 AI IN BIOTECHNOLOGY MARKET: CAGR PROJECTIONS 51
FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 52
FIGURE 9 DATA TRIANGULATION 53
FIGURE 10 AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION) 56
FIGURE 11 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2024 VS. 2029 (USD MILLION) 57
FIGURE 12 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,
2024 VS. 2029 (USD MILLION) 57
FIGURE 13 AI IN BIOTECHNOLOGY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 58
FIGURE 14 AI IN BIOTECHNOLOGY MARKET: GEOGRAPHICAL SNAPSHOT 59
FIGURE 15 GROWING FOCUS ON COST-EFFECTIVE PROCESSES AND FAVORABLE GOVERNMENT SUPPORT AND FUNDING TO DRIVE MARKET 60
FIGURE 16 NORTH AMERICA TO DOMINATE AI IN BIOTECHNOLOGY MARKET DURING FORECAST PERIOD 61
FIGURE 17 PHARMACEUTICAL COMPANIES IN NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2023 62
FIGURE 18 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 63
FIGURE 19 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 63
FIGURE 20 AI IN BIOTECHNOLOGY MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 64
FIGURE 21 AI IN BIOTECHNOLOGY MARKET: ECOSYSTEM ANALYSIS 72
FIGURE 22 AI IN BIOTECHNOLOGY MARKET: VALUE CHAIN ANALYSIS 74
FIGURE 23 AI IN BIOTECHNOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS 76
FIGURE 24 PATENT PUBLICATION TRENDS IN AI IN BIOTECHNOLOGY MARKET, 2015–2024 84
FIGURE 25 PATENT ANALYSIS OF AI IN BIOTECHNOLOGY MARKET,
JANUARY 2015–JANUARY 2025 85
FIGURE 26 EVOLUTION OF AI IN BIOTECHNOLOGY MARKET 90
FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP 3 END USERS 94
FIGURE 28 KEY BUYING CRITERIA FOR TOP 3 END USERS 95
FIGURE 29 TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 96
FIGURE 30 AI IN BIOTECHNOLOGY MARKET: INVESTMENT & FUNDING SCENARIO 98
FIGURE 31 MARKET POTENTIAL OF AI/GENERATIVE AI ON AI IN BIOTECHNOLOGY SOLUTIONS 99
FIGURE 32 NUMBER OF AI-DISCOVERED MOLECULES IN CLINICAL TRIALS 115
FIGURE 33 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET SNAPSHOT 161
FIGURE 34 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET SNAPSHOT 221
FIGURE 35 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET, BETWEEN JANUARY 2021 AND JANUARY 2025 303
FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET,
2019–2023 (USD BILLION) 304
FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET (2023) 305
FIGURE 38 RANKING OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET, 2023 308
FIGURE 39 AI IN BIOTECHNOLOGY MARKET:
COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 309
FIGURE 40 AI IN BIOTECHNOLOGY MARKET: COMPANY FOOTPRINT 310
FIGURE 41 AI IN BIOTECHNOLOGY MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023 316
FIGURE 42 EV/EBITDA OF KEY VENDORS 319
FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF AI IN BIOTECHNOLOGY SOLUTION VENDORS 319
FIGURE 44 AI IN BIOTECHNOLOGY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 320
FIGURE 45 NVIDIA CORPORATION: COMPANY SNAPSHOT (2024) 326
FIGURE 46 ILLUMINA, INC.: COMPANY SNAPSHOT (2023) 330
FIGURE 47 EXSCIENTIA: COMPANY SNAPSHOT (2023) 335
FIGURE 48 SCHRÖDINGER, INC.: COMPANY SNAPSHOT (2023) 342
FIGURE 49 RECURSION PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2023) 345
FIGURE 50 SOPHIA GENETICS: COMPANY SNAPSHOT (2023) 348
FIGURE 51 PREDICTIVE ONCOLOGY: COMPANY SNAPSHOT (2023) 352
FIGURE 52 BENEVOLENTAI: COMPANY SNAPSHOT (2023) 355
FIGURE 53 EUROFINS DISCOVERY: COMPANY SNAPSHOT (2023) 358
FIGURE 54 XTALPI INC.: COMPANY SNAPSHOT (2023) 362
MarketsandMarkets（マーケッツアンドマーケッツ）は広範な市場を対象にした市場調査レポートを出版しています。世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- ご注文後2営業日以内
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
割引可能なレポートが多数ございます。価格・サンプルについてはお気軽にご相談ください。
最新調査レポート
- 沈降シリカ市場 – 2030年までの世界予測 2025-03-07
- スマートメーター市場 – 2030年までの世界予測 2025-03-07
- 産業用計測市場 – 2030年までの世界予測 2025-03-06
- 精密ろ過膜市場- 2029年までの世界予測 2025-03-06
- グリーンテクノロジーと持続可能性市場 – 2030年までの世界予測 2025-03-06